000			nab a22 7a 4500
999			_c16556 _d16556
003			PC16556
005			20210730143524.0
008			210726b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91482 _aGrande García, Carlos _eHematología y Hemoterapia
245	0	0	_aPrognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. _h[artículo]
260			_bCancer, _c2014
300			_a120(24):3958-64.
500			_aFormato Vancouver: Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, González Campos J et al; PETHEMA Group, Spanish Society of Hematology. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer. 2014 Dec 15;120(24):3958-64.
501			_a PMID: 25116331
504			_aContiene 21 referencias
520			_aBackground: The karyotype is a predictor of outcomes in adults with acute lymphoblastic leukemia (ALL). The unfavorable prognostic significance of complex karyotype (CK) has been reported, whereas the prognostic relevance of monosomal karyotype (MK) has not been consistently evaluated. We aimed to assess the prognostic value of CK and MK in adults with ALL treated with risk-adapted protocols of the Spanish PETHEMA Group. Methods: The karyotypes of 881 adult ALL patients treated according to the protocols of the PETHEMA Group between 1993 and 2012 were centrally reviewed. CK and MK were assessed according to Moorman's criteria, and Breem's criteria, respectively. Specific analyses according to the risk groups and to the presence of t(9:22) were performed. Results: Of 364 evaluable patients 33 (9.2%) had CK, and 68 of 535 evaluable patients (12.8%) had MK. Complete remission rate, remission duration, and overall survival were not significantly different according to the presence of CK or MK in the whole series, according to the B or T lineage, in the high-risk group, or in patients with t(9;22), regardless of imatinib treatment, and in patients who received chemotherapy alone or chemotherapy followed by stem cell transplantation Conclusions: Our study shows that CK and MK were not associated with a worse prognosis in adult patients with ALL treated with risk-adapted or subtype-oriented protocols. In patients with Ph+ ALL, MK did not have an impact on prognosis irrespective of imatinib treatment.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16556.pdf _ySolicitar documento
942			_2ddc _cART _n0